Aardvark Therapeutics (AARD) Change in Accured Expenses (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 189.36% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 62.12% YoY), and the FY2025 full-year result was $6.4 million, up 363.18% from the prior year.
• Change in Accured Expenses retreated to -$1.3 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q4 2025 to a low of -$1.3 million in Q1 2026.
• A 3-year average of $726666.7 and a median of $614000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 72500.0% in 2025 and tumbled 189.36% in 2026, its largest moves.
• Tracing AARD's Change in Accured Expenses over 3 years: stood at -$3000.0 in 2024, then surged by 72500.0% to $2.2 million in 2025, then plunged by 158.01% to -$1.3 million in 2026.
• Business Quant data shows AARD's Change in Accured Expenses at -$1.3 million in Q1 2026, $2.2 million in Q4 2025, and $1.0 million in Q3 2025.